Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26213169 | 0.90 | CYP3A4 (0.43) | L3MBTL1KDM1AHDAC6CARM1PRMT6 | |
| SCHEMBL26213116 | 0.89 | KDM1A (0.43) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL26213112 | 0.89 | CARM1 (0.43) | L3MBTL1GAAKDM1AHDAC6CARM1 | |
| SCHEMBL30270456 | 0.89 | CARM1 (0.43) | L3MBTL1GAAKDM1AHDAC6CARM1 | |
| SCHEMBL26213109 | 0.86 | KDM1A (0.41) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL26213059 | 0.86 | KMT2A (0.49) | L3MBTL1KDM1AKMT2A | |
| SCHEMBL30270433 | 0.81 | PRMT6 (0.43) | L3MBTL1KDM1AHDAC6CARM1PRMT6 | |
| SCHEMBL26213120 | 0.81 | PRMT6 (0.43) | L3MBTL1KDM1AHDAC6CARM1PRMT6 | |
| SCHEMBL26213069 | 0.77 | SIGMAR1 (0.44) | L3MBTL1GAAKDM1ASMN1; SMN2KMT2A | |
| SCHEMBL26213173 | 0.77 | SMN1; SMN2 (0.47) | L3MBTL1GAAKDM1ACARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | L3MBTL1 3699/4885GAA 3414/4885KDM1A 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.